Tuberculosis

Lancet

Volumn 362, Issue 9387, 2003, Pages 887-899

  Frieden, Thomas R ^a   Sterling, Timothy R ^b   Munsiff, Sonal S ^a,c   Watt, Catherine J ^d   Dye, Christopher ^d  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DISULFIRAM; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ABDOMINAL CRAMP; ACID FAST BACTERIUM; AFRICA; ARTHRALGIA; BCG VACCINATION; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COLOR BLINDNESS; CONFERENCE PAPER; DEPRESSION; DEVELOPING COUNTRY; DNA FINGERPRINTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EOSINOPHILIA; ERYTHEMA MULTIFORME; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; HYPOACUSIS; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; INFECTION CONTROL; INSOMNIA; LIVER TOXICITY; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; RASH; SEIZURE; SHORT COURSE THERAPY; SIDE EFFECT; SPUTUM SMEAR; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; VESTIBULAR DISORDER; VISUAL DISORDER;

EID: 0141853344     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14333-4     Document Type: Conference Paper

References (166)

1. Iseman M.D. A clinician's guide to tuberculosis. 2000;Lippincott Williams and Wilkins, Philadelphia.
2. Corbett E.L., Watt C.J., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 163:2003;1009-1021.
3. Global tuberculosis control: surveillance, planning, financing, WHO Report 2003 (WHO/CDS/TB/2003.316). 2003;WHO, Geneva.
4. Shilova M.V., Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond Biol Sci. 356:2001;1069-1075.
5. Anti-tuberculosis drug resistance in the world. Report no 2. Prevalence and trends (WHO/CDS/TB/2000.278). 2000;WHO, Geneva.
6. Corbett E.L., Steketee R.W., ter Kuile F.O., Latif A.S., Kamali A., Hayes R.J. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 359:2002;2177-2187.
7. Wells W.F. On air-borne infection: study II, droplets and droplet nuclei. Am J Hygiene. 20:1934;611-618.
8. Louden R.G., Roberts R.M. Droplet expulsion from the respiratory tract. Am Rev Respir Dis. 95:1966;435-442.
9. Riley R.L., Mills C.C., Nyka W., et al. Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in a tuberculosis ward. Am J Hygiene. 70:1959;185-196.
10. Comstock G.W., Livesay V.T., Woolpert S.F. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 99:1974;131-138.
11. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 19:1976;1-63.
12. Schluger N.W., Rom W.N. The host immune response to tuberculosis. Am J Respir Crit Care Med. 157:1998;679-691.
13. Sodhi A., Gong J., Silva C., Qian D., Barnes P.F. Clinical correlates of interferon-gamma production in patients with tuberculosis. Clin Infect Dis. 25:1997;617-620.
14. Ellner J.J. Review: The immune response in human tuberculosis: implications for tuberculosis control. J Infect Dis. 176:1997;1351-1359.
15. Ting L.M., Kim A.C., Cattamanchi A., Ernst J.D. Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. J Immunol. 163:1999;3898-3906.
16. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon-gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 178:1993;2249-2254.
17. Flynn J.L., Goldstein M.M., Chan J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 2:1995;561-572.
18. Bean A.G., Roach D.R., Briscoe H., et al. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 162:1999;3504-3511.
19. Flynn J.L., Ernst J.D. Immune responses in tuberculosis. Curr Opin Immunol. 12:2000;432-436.
20. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 161:2000;S221-S247.
21. Wilkinson R.J., Llewelyn M., Toossi Z., et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 355:2000;618-621.
22. Karyadi E., West C.E., Schultink W., et al. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am J Clin Nutr. 75:2002;720-727.
23. Hirsch C.S., Toossi Z., Othieno C., et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis. 180:1999;2069-2073.
24. Sterling T.R., Dorman S.E., Chaisson R.E., et al. HIV-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis. 33:2001;976-982.
25. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 345:2001;1098-1104.
26. Jouanguy E., Lamhamedi-Cherradi S., Altare F., et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest. 100:1997;2658-2664.
27. Altare F., Ensser A., Breiman A., et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis. 184:2001;231-236.
28. Comstock G.W. Tuberculosis in twins: a re-analysis of the Prophit survey. Am Rev Respir Dis. 117:1978;621-624.
29. Stead W.W. Genetics and resistance to tuberculosis. Ann Intern Med. 116:1992;937-941.
30. Singh S.P., Mehra N.K., Dingley H.B., Pande J.N., Vaidya M.C. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. J Infect Dis. 148:1983;676-681.
31. Goldfeld A.E., Delgado J.C., Thim S., et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA. 279:1998;226-228.
32. Bellamy R., Ruwende C., Corrah T., McAdam K.P., Whittle H.C., Hill A.V. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 338:1998;640-644.
33. Greenwood C.M., Fujiwara T.M., Boothroyd L.J., et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am J Hum Genet. 67:2000;405-416.
34. Bellamy R., Ruwende C., Corrah T., et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis. 179:1999;721-724.
35. Wilkinson R.J., Patel P., Llewelyn M., et al. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med. 189:1999;1863-1874.
36. Awomoyi A., Marchant A., Howson J.M.M., McAdam K.P., Blackwell J.M., Newport M.J. Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J Infect Dis. 186:2002;1808-1814.
37. Delgado J.C., Baena A., Thim S., Goldfield A.E. Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis. 186:2002;1463-1468.
38. Shafer R.W., Edlin B.R. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis. 22:1996;683-704.
39. Rieder H.L., Snider D.E. Jr, Cauthen G.M. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis. 141:1990;347-351.
40. Rieder H.L. Epidemiologic basis of tuberculosis control. 1999;International Union Against Tuberculosis and Lung Disease, Paris.
41. Roper W.H., Waring J.J. Primary serofibrinous pleural effusion in military personnel. Am Rev Tuberc. 71:1955;616-634.
42. Thwaites G., Chau T.T., Mai N.T., Drobniewski F., McAdam K., Farrar J. Tuberculous meningitis. J Neurol Neurosurg Psychiatry. 68:2000;289-299.
43. Berenguer J., Moreno S., Laguna F., et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med. 326:1992;668-672.
44. Goldfarb D., Saimn L. Tuberculosis of the genitourinary tract. Rom W.N., Garay S. Tuberculosis. 1996;609-622 Little Brown, New York.
45. World H. World Health Organization Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes (WHO/CDS/TB/.13). 3rd edn: 2003;2003 WHO, Geneva.
46. Enarson D.A., Rieder H.L., Arnadottir T., Trébucq A. Management of tuberculosis: a guide for low-income countries. 5th edn: 2000;1-89 International Union Against Tuberculosis and Lung Disease, Paris.
47. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 161:2000;1376-1395.
48. Hesseling A.C., Schaaf H.S., Gie R.P., Starke J.R., Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis. 6:2002;1038-1045.
49. Laboratory services in tuberculosis control (WHO/TB/98.258 [Pt 2]). 1998;WHO, Geneva.
50. Shaw J.B., Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc. 69:1954;724-732.
51. Grzybowski S., Barnett G.D., Syblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc. 50:1975;90-106.
52. Behr M.A., Warren S.A., Salamon H., et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 353:1999;444-449.
53. Crampin A.C., Floyd S., Mwaungulu F., et al. Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. Int J Tuberc Lung Dis. 5:2001;994-999.
54. Kubica G., Kent K. Public health mycobacteriology: a guide for the level III laboratory. 1985;60-63 Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta.
55. Morgan M.A., Horstmeier C.D., DeYoung D.R., Robers G.D. Comparison study of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol. 18:1983;384-388.
56. Harries A.D., Maher D. TB/HIV: a clinical manual (WHO/TB/96.200: 38). 1996;WHO, Geneva.
57. Perlman D.C., El Sadr W.M., Nelson E.T., et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis. 25:1997;242-246.
58. Burman W.J., Reves R.R. Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment. Clin Infect Dis. 31:2000;1390-1395.
59. Nivin B., Fujiwara P.I., Hannifin J., Kreiswirth B.N. Cross-contamination with Mycobacterium tuberculosis: an epidemiological and laboratory investigation. Infect Control Hosp Epidemiol. 19:1998;500-503.
60. Woods G.L. Susceptibility testing for mycobacteria. Clin Infect Dis. 31:2000;1209-1215.
61. Cooksey R.C., Morlock G.P., Glickman S., Crawford J.T. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol. 35:1997;1281-1283.
62. Jacobs W.R. Jr, Barletta R.G., Udani R., et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science. 260:1993;819-822.
63. Piatek A.S., Tyagi S., Pol A.C., et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol. 16:1998;359-363.
64. Piatek A.S., Telenti A., Murray M.R., et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother. 44:2000;103-110.
65. Heifets L.B., Cangelosi G.A. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 3:1999;564-581.
66. Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med. 155:1997;1804-1814.
67. Behr M.A., Small P.M. Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis. 25:1997;806-810.
68. Von Pirquet C. Frequency of tuberculosis in childhood. JAMA. 52:1909;675-678.
69. Seibert F.B., Glen J.T. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. Am Rev Tuberc. 44:1941;9-24.
70. Lee E., Holzman R.S. Evolution and current use of the tuberculin test. Clin Infect Dis. 34:2002;365-370.
71. Huebner R.E., Schein M.F., Bass J.B. The tuberculin skin test. Clin Infect Dis. 17:1993;968-975.
72. Mazurek G.H., Villarini M.E. Guidelines for using the QuantiFeron-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 52:(RR-2):2003;15-18.
73. Kimura M., Converse P.J., Astemborski J., et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis. 179:1999;1297-1300.
74. Bellete B., Coberly J., Barnes G.L., et al. Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis. 34:2002;1449-1456.
75. Converse P.J., Jones S.L., Astemborski J., Vlahov D., Graham N.M. Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis. 176:1997;144-150.
76. Mazurek G.H., LoBue P.A., Daley C.L., et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 286:2001;1740-1747.
77. Ewer K., Deeks J., Alvarez L., et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 361:2003;1168-1173.
78. David H.L. Probability distribution of drug resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 20:1970;810-814.
79. Fox W., Ellard G.A., Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 3:1999;S231-S279.
80. Iseman M.D. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 329:1993;784-791.
81. Treatment of tuberculosis. Am J Respir Crit Care Med. 167:2003;603-662.
82. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 53:1998;536-548.
83. Girling D.J. The chemotherapy of tuberculosis. Ratledge C., Stanford J., Grange J.M. Biology of the mycobacteria: clinical aspects of mycobacterial disease. 1989;285-323 Academic Press, Cambridge.
84. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide: results at 30 months. Am Rev Respir Dis. 143:1991;700-706.
85. Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis I. BMJ. 287:1993;33-35.
86. Weis S.E., Slocum P.C., Blais F.X., et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 334:1994;1179-1184.
87. Chaulk P.C., Kazandjian V.A. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 279:1998;943-947.
88. Kamolratanakul P., Sawert H., Lertmaharit S., et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg. 93:1999;552-557.
89. Mitchison D.A. Basic mechanisms of chemotherapy. Chest. 76:1979;S771-S781.
90. Frieden T.R. Directly observed treatment for tuberculosis. Lancet. 353:1999;146.
91. Pungrassami P., Johnsen A.P., Chongsuvivatwong V., Olsen J., Sorensen H.T. Practice of directly observed treatment (DOT) in southern Thailand: comparison between different types of observers. Int J Tuberc Lung Dis. 6:2002;389-395.
92. Frieden T., Sbarbaro J.A. The slippery slope to sloppy DOTS. Int J Tuberc Lung Dis. 6:2002;371-372.
93. Ormerod L.P., Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuberc Lung Dis. 77:1996;37-42.
94. Girling D.J. Adverse effects of antituberculosis drugs. Drugs. 23:1982;56-74.
95. Rieder H.L. Interventions for tuberculosis control and elimination. 2002;International Union Against Tuberculosis and Lung Disease, Paris.
96. Bureau of Tuberculosis Control. Clinical polices and protocols, 3rd edn. New York City Department of Health; 1999. Available from: URL: http://www.nyc.gov/html/doh/pdf/tb/manu.pdf (accessed June 24, 2003).
97. Grosset J., Truffot-Pernot C., Cambau E. Bacteriology of tuberculosis. Reichman L.B., Hershfield E.S. Tuberculosis: a comprehensive international approach. 2nd edn: 2000;157-185 Marcel Dekker, New York.
98. Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. BMJ. 290:1985;1106-1108.
99. Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Int Orthop. 23:1999;73-81.
100. Balasubramanian R., Ramachandran R. Management of non-pulmonary forms of tuberculosis: review of TRC studies over two decades. Indian J Pediatr. 67:2000;S34-S40.
101. Yuen A.P.W., Wong S.H.W., Tam C.M., Chan S.L., Wei W.I., Lau A.K. Prospective randomised study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. Otolaryngol Head Neck Surg. 116:1997;189-192.
102. Donald P.R., Schoeman J.F., Van Zyl L.E., De Villiers J.N., Pretorius M., Springer P. Intensive short course chemotherapy in the management of tuberculosis meningitis. Int J Tuberc Lung Dis. 2:1998;704-711.
103. Girgis N.I., Farid Z., Kilpatrick M.E., Sultan Y., Mikhail I.A. Dexamthasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J. 10:1991;179-183.
104. Schoeman J.F., Van Zyl L.E., Laubscher J.A., Donald P.R. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculosis meningitis. Pediatrics. 99:1997;226-231.
105. Strang J.I., Kakaza H.H., Gibson D.G., Girling D.J., Nunn A.J., Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 2:1987;1418-1422.
106. Strang J.I., Kakaza H.H., Gibson D.G., et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 2:1998;759-764.
107. Hakim J.G., Ternouth I., Mushangi E., Siziya S., Robertson V., Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 84:2000;183-188.
108. Lee C.H., Wang W.J., Lan R.S., Tsai Y.H., Chiang Y.C. Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo-controlled, randomized study. Chest. 94:1988;1256-1259.
109. Wyser C., Walzl G., Smedema J.P., Swart F., Schalkwyk M.V., Wal B.W. Corticosteroids in the treatment of tuberculosis pleurisy: a double-blind, placebo-controlled, randomised study. Chest. 110:1996;333-338.
110. Dooley D.P., Carpenter J.L., Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis. 25:1997;872-887.
111. Brost B.C., Newman R.B. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am. 24:1997;659-673.
112. Valerio G., Bracciole P., Manisco V., Quitaderno M., Legari G., Bellanova S. Long-term tolerance and effectiveness of moxafloxacin therapy for tuberculosis: preliminary results. J Chemother. 15:2003;66-70.
113. The transfer of drugs and other chemicals into human milk. Pediatrics. 108:2001;776-789.
114. Peloquin C.A. Antituberculosis drugs: pharmacokinetics. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. 1991;59-88 CRC Press, Boca Raton.
115. Malone R.S., Fish D.N., Spiegel D.M., Childs J.M., Peloquin C.A. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Chest. 116:1999;984-990.
116. Malone R.S., Fish D.N., Spiegel D.M., Childs J.M., Peloquin C.A. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med. 159:1999;1580-1584.
117. Nunn P., Kibuga D., Gathua S., et al. Cutaneous hypersensitivity reactions due to thioacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 337:1991;627-630.
118. Okwera A., Whalen C., Byekwaso F., et al. Randomised trial of thioacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet. 344:1994;1323-1328.
119. Elliott A.M., Halwiindi B., Hayes R.J., et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 89:1995;78-82.
120. Harries A.D. Tuberculosis in Africa: clinical presentation and management. Pharmacol Ther. 73:1997;1-50.
121. Alpert P.L., Munsiff S.S., Gourevitch M.N., Greenberg B., Klein R.S. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis. 24:1997;661-668.
122. Murray J., Sonnenberg P., Shearer S.C., Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 159:1999;733-740.
123. Alwood K., Keruly J., Moore-Rice K., Stanton D.L., Chaulk C.P., Chaisson R.E. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV infected patients. AIDS. 8:1994;1103-1108.
124. Driver D.R., Munsiff S.S., Li J., Kundamal N., Osahan S.S. Relapse in persons treated for drug-susceptible tuberculosis in a population with high co-infection with human immunodeficiency virus in New York City. Clin Infect Dis. 33:2001;1762-1769.
125. Elliott A.M., Halwiindi B., Hayes R.J., et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg. 98:1995;9-21.
126. Mallory K.F., Churchyard G.J., Kleinschmidt I., De Cock K.M., Corbett E.L. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis. 4:2000;455-462.
127. Connolly C., Reid A., Davies G., Sturm W., McAdam K., Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS. 13:1999;1543-1547.
128. Sterling T.R., Alwood K., Gachuhi R., et al. Relapse rates after short-course (6 month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 13:1999;1899-1904.
129. Sonnenberg P., Murray J., Glynn J.R., Shearer S., Kambashi B., Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 358:2001;1687-1693.
130. Burman W.J., Gallicano K., Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis. 28:1999;419-430.
131. Gonzalez-Montaner L.J., Natal S., Youngchaiyud P., Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuberc Lung Dis. 75:1994;341-347.
132. Schwander S., Rüsch-Gerdes S., Mateega A., et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tuberc Lung Dis. 76:1995;210-218.
133. McGregor M.M., Olliaro P., Wolmarans L., et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 154:1996;1462-1467.
134. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep. 47:(RR-20):1998;1-58.
135. Burman W.J., Jones B.E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med. 164:2001;7-12.
136. Munsiff S.S., Fujiwara P.I. Treatment of tuberculosis in patients taking antiretrovirals [erratum AIDS Reader 2000; 10: 206]. AIDS Reader. 10:2000;102-108.
137. Notice to readers: acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51: 214-15.
138. Vernon A., Burman W., Benator D., Khan A., Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet. 353:1999;1843-1847.
139. Narita M., Ashkin D., Hollender E.S., Pitchenik A.E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 158:1998;157-161.
140. Wendel K.A., Alwood K., Gachuhi R., Chaisson R.E., Bishai W.R., Sterling T.R. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest. 120:2001;193-197.
141. Chambers S.T., Hendrickse W.A., Record C., Rudge P., Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet. 2:1984;181-184.
142. Wendland T., Furrer H., Vernazza P.L., et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS. 13:1999;1857-1862.
143. Navas E., Martin-Davila P., Moreno L., et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med. 162:2002;97-99.
144. Frieden T.R., Sherman L.F., Maw K.L., et al. A multi-institutional outbreak of highly drug resistant tuberculosis. JAMA. 276:1996;1229-1235.
145. An expanded DOTS framework for effective tuberculosis control (WHO/CDS/TB/2002.297). 2002;WHO, Geneva.
146. World Health Organization. 44th World Health Assembly (WHA44/1991/REC/1) ; supplemented by 53rd World Health Assembly, Report by the Director General, Provisional Agenda Item 12.1, A53/5; May 5, 2000.
147. Dye C., Watt C.J., Bleed D.M., Williams B.G. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis. 83:2003;35-43.
148. Dye C., Garnett G.P., Sleeman K., Williams B.G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet. 352:1998;1886-1891.
149. Dye C. Tuberculosis 2000-2010: control, but not elimination. Int J Tuberc Lung Dis. 4:2000;S146-S152.
150. Suárez P., Watt C.J., Alarcon E., et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 184:2001;473-478.
151. Dye C., Fengzeng Z., Scheele S., Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol. 29:2000;558-564.
152. Khatri G.R., Frieden T.R. Controlling tuberculosis in India. N Engl J Med. 347:2002;1420-1425.
153. Jones J.L., Hanson D.L., Dworkin M.S., DeCock K.M. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis. 4:2000;1026-1031.
154. Badri M., Wilson D., Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 359:2002;2059-2064.
155. Fine P.E.M. BCG vaccines and vaccination. Reichman L.B., Hershfield E.S. Tuberculosis: a comprehensive international approach. 2000;503-522 Marcel Dekker, New York.
156. Core information for the development of immunization policy: 2002 update (WHO/V&B/02.28). 2002;WHO, Geneva.
157. Styblo K. Epidemiology of tuberculosis (selected papers). 1991;Royal Netherlands Tuberculosis Association (KNCV), The Hague.
158. Lotte A., Wasz-Hockert O., Poisson N. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 63:1988;47-59.
159. Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 3:1999;847-850.
160. Jasmer R.M., Saukkonen J.J., Blumberg H.M., et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 137:2002;640-647.
161. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States. MMWR Morb Mortal Wkly Rep 2001; 50: 733-35.
162. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51: 998-99.
163. Wilkinson D., Squire S.B., Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo-controlled trials. BMJ. 317:1998;625-629.
164. Johnson J.L., Okwera A., Hom D.L., et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 15:2001;2137-2147.
165. Quigley M.A., Mwinga A., Hosp M., et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 15:2001;215-222.
166. Murray C.J., DeJonghe E., Chum H.J., Nyangulu D.S., Salomao A., Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet. 338:1991;1305-1308.